Alpine Immune Sciences Announces First Patient Dosed in NEON-1 Phase 1 Trial of ALPN-202 in Patients with Advanced Malignancies

Stock Information for Alpine Immune Sciences Inc.

Loading

Please wait while we load your information from QuoteMedia.